Skip to main content

Profile: Ruiwen Zhang

Ruiwen Zhang
Ruiwen Zhang, M.D., Ph.D., D.A.B.T.
Robert L. Boblitt Endowed Professor in Drug Discovery
Professor of Pharmacology and Toxicology
Director of UH Center for Drug Discovery
Health 2
University of Houston College of Pharmacy
4849 Calhoun Road, Room 7034
Houston, TX 77204-5037

Office: 713-743-6840
Fax: 713-743-1884
rzhang27@central.uh.edu

Education & Certifications

Ph.D. in Toxicology and Occupational Epidemiology, Shanghai Medical University (now Fudan University Shanghai Medical College)

M.D., Shanghai Medical University (now Fudan University Shanghai Medical College)

Post-Doc/Clinical Pharmacology Fellow, University of Alabama School of Medicine, Birmingham, AL

Diplomate, American Board of Toxicology, 1999-

Research Interests

Drug discovery and development; Molecular, biochemical, and clinical pharmacology and experimental therapeutics; Molecular cancer biology; Preclinical Pharmacology and Toxicology; Clinical Pharmacology and Clinical Trials; Pharmacogenetics/Pharmacogenomics; Gene regulation, gene silencing, and molecular targeting; Biotechnology and biopharmaceuticals; Cancer prevention and biomarkers; Nutrition and health

Research Support

Sponsor: NIH/NCI (R01 CA214019):
Title: Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy
PI: Ruiwen Zhang, M.D., Ph.D.
Funding Period: Funding Period: 9/4/17-8/31/2022
Total budget: $2,907,835

Sponsor: NIH/NCI (R01 CA 186662):
Title: Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
PI: Ruiwen Zhang, M.D., Ph.D.
Funding Period: 4/1/14-2/29/2021
Total budget: $2,441,745

Sponsor: American Cancer Society
Title: Targeting MDM2 Oncogene for Breast Cancer Therapy
PI: Wei Wang, M.D., Ph.D.; Co-Investigator: Ruiwen Zhang, M.D., Ph.D.
Funding Period: 7/1/15-12/31/2020
Total budget: $780,889

Honors and Awards

  • Fellow, National Academy of Inventors (NAI; 2018-)
  • Fellow, American Association for the Advancement of Science (AAAS; 2009-)
  • Diplomate (DABT, 1999-) and Board Director (2009-2013), American Board of Toxicology
  • President’s Excellence in Research Award, Texas Tech University Health Science Center, TX (2015)
  • Outstanding Service Award, Society of Chinese Bioscientists in America (SCBA; 2010)
  • U.S. FDA Advisory Committee Service Award (2008)

Selected Publications

Dr. Zhang’s NCBI Bibliography link: https://www.ncbi.nlm.nih.gov/myncbi/ruiwen.zhang.1/bibliography/public/

Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev 2020; 40(3):856-880. doi: 10.1002/med.21637.

Wang W, Zafar A, Rajaei M, Zhang R. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells 2020, 9, 1176; doi:10.3390/cells9051176

Wang W, Hu B, Qin JJ, Cheng J, Li X, Rajaei MX, Fan J, Yang XR, Zhang R. A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance. Genes Dis. 2019; June 19

Punganuru SR, Madala HR, Arutla V, Zhang R, Srivenugopal KS. Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging. Sci Rep. 2019 Jun 12;9(1):8577.

Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 Sep 10;459:156-167.

Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018 Jul 20;5(3):204-219. eCollection 2018 Sep.

Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 Oct 1;78(19):5656-5667.

Deokar H, Deokar M, Wang W, Zhang R, Buolamwini J. QSAR Studies of Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Medicinal Chemistry Research. 2018; 27 (11-12), 2466–2481.

Cao H, Zhang R, Zhang W. CTLA-4 interferes with the HBV-specific T cell immune response (Review). Int J Mol Med. 2018 Aug;42(2):703-712.

Wang W, Qin JJ, Li X, Tao G, Wang Q, Wu X, Zhou J, Zi X, Zhang R. Prevention of prostate cancer by natural product MDM2 inhibitor GS25: In vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 May 12.

Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R. Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018 Jan 17;9:5. eCollection 2018.

Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R, Wang H. Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein. Cell Discov. 2017 Nov 21;3:17042.

Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b]indole Derivatives as Broad-Spectrum Potent Anticancer Agents. Drug Des. 2017 Mar;6(1). pii: 143.

Qin JJ, Li X, Wang W, Zi X, Zhang R. Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017 Dec 14;8:917. eCollection 2017.

Ba Q, Li X, Huang C, Li J, Fu Y, Chen P, Duan J, Hao M, Zhang Y, Li J, Sun C, Ying H, Song H, Zhang R, Shen Z, Wang H. BCCIPβ modulates the ribosomal and extraribosomal function of S7 through a direct interaction. J Mol Cell Biol. 2017 Jun 1;9(3):209-219.

Xue B, Wang W, Qin JJ, Nijampatnam B, Murugesan S, Kozlovskaya V, Zhang R, Velu S, Kharlampieva E. Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes. Acta Biomater. 2017; S1742-7061(17)30356-2.

Qin JJ, Wang W, Sarkar S, Zhang R. Oral Delivery of Anti-MDM2 Inhibitor SP141 with FcRn-targeted Nanoparticles to Treat Breast Cancer and Metastasis. J Controlled Release 2016;237: 101-14.

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev 2015;35: 1220-67.

Voruganti S, Xu F, Qin JJ, Guo Y, Sarkar S, Gao M, Zheng Z, Wang MH, Zhou JW, Qian B, Zhang R, Wang W. RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Lett. 2015; 369:386-395

Wang W, Nag S, Zhang X, Wang MH, Wang H, Zhou J, Zhang R. Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. Med Res Rev 2015;35:225-85.

Wang W, Qin JJ, Voruganti S, Srivenugopal KS, Nag S, Patil S, Sharma H, Wang MH, Buolamwini JK, Zhang R. A Pyrido[b]indole MDM2 Inhibitor, SP-141, Exerts Potent Therapeutic Effects in Breast Cancer Models. Nature Communications 2014;5:5086.

Qin JJ, Nag S, Wang W, Zhou J, Zhang WD, Wang H, Zhang R. NFAT as cancer target: Mission possible? BBA Reviews on Cancer 2014;1846:297-311.

Wang W, Qin JJ, Voruganti S, Wang MH, Sharma H, Patil S, Zhou J, Wang H, Mukhopadhyay D, Buolamwini JK, Zhang R. Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology 2014;147:893-902.

Zhang X, Wang W, Wang H, Wang M-H, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene 2013;32:2782-91.

Yao HP, Zhou YQ, Zhang R, Wang MH. MSP-RON Signaling in Cancer: Pathogenesis and Therapeutic Potential. Nature Reviews Cancer 2013; 13(7):466-481.

Li X, Yang X, Liu Y, Gong N, Yao W, Chen P, Qin J, Jin H, Li J, Chu R, Shan L, Zhang R, Zhang W, Wang H. Japonicone A suppresses growth of Burkitt’s lymphoma cells through its effect on NF-κB. Clin Cancer Res. 2013; 19(11):2917-2928.

Zhang X, Zhang Z, Chen J, Li M, Wang W, Xu W, Wang H, Zhang R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem 2012;287:30468-76.

Nag SA, Qin JJ, Wang W, Wang M, Wang H, Zhang R. Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front. Pharmacol. 2012; 3:25. doi:10.3389/fphar.2012.00025

Ma Q, Guin S, Padhye SS, Zhou Y-Q, Zhang RW, Wang M-H. Ribosomal Protein S6 Kinase (RSK)-2 as a Central Effector Molecule in RON Receptor Tyrosine Kinase Mediated Epithelial to Mesenchymal Transition Induced by Macrophage-Stimulating Protein. Mol Cancer 2011; 10: 66 (15 pages)

Duan J, Ba Q, Hao M, Wang Z, Hu P, Li X, Zhang D, Zhang R, Wang H. Knockdown of Ribosomal Protein S7 Causes Developmental Abnormalities via p53 Dependent and Independent Pathways in Zebrafish. Int J Biochem Cell Biol. 2011; 43(8):1218-27.

Yao HP, Zhou YQ, Ma Q, Guin S, Padhye SS, Zhang RW, Wang MH. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells. Mol Cancer. 2011; 10:82 (12 pages).

Xu H, Zhang Z, Li M, Zhang R. MDM2 promotes proteasomal degradation of p21Waf1 via a Conformation Change. J Biol Chem 2010; 285(24):18407-14.

Zhang X, Xu W, Qian H, Zhu W, Zhang R. Mesenchymal stem cells modified to express lentivirus-TNFα-Tumstatin45-132 inhibit the growth of prostate cancer. J Cell Mol Med. 2011; 15 (2): 433-444.

Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R. In Vitro and In Vivo Anti-cancer Activity of Novel Synthetic Makaluvamine Analogs. Clin Cancer Res 2009;15:3511-8.

Wang W, Rayburn ER, Zhao Y, Wang H, Zhang R. Novel Ginsenosides 25-OH-PPD and 25-OCH3-PPD as Experimental Therapy for Pancreatic Cancer: Anticancer Activity and Mechanisms of Action. Cancer Lett 2009; 278(2):241-8.

Chen D, Zhang J, Li M, Rayburn ER, Wang H, Zhang R. RYBP (Ring-1 and YY1-binding protein) stabilizes p53 by modulating MDM2. EMBO Reports 2009;10:166-72.

Rayburn E, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Drug Discov Today. 2008; 13(11-12):513-521.

Hou J, Wang D, Zhang R, Wang H. Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action. Clin Cancer Res. 2008; 14(17):5519-5530.

Zhang Z, Zhang R. Proteasome activator PA28gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO Journal 2008;27:852-64.

Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H, Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 2007;26:5029-37.

Li M, Zhang Z, Hill D, Wang H, Zhang R. Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway. Cancer Res. 2007;67:1988-96.

LaCasse EC, Cherton-Horvat GG, Hewitt KE, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006;12(17):5231-5241

Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anti-cancer activity and potentiation of antibody therapy. Mol Cancer Ther 2006; 5(8): 2106-2114

Wang H, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 2006; 5(6):1585-1592

Li M, Zhang Z, Hill D, Chen X, Wang H, Zhang R. Genistein, a dietary isoflavone, down-regulates MDM2 oncogene at both transcriptional and post-translational levels Cancer Res 2005;65:8200-8.

Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24(48):7238-7247.

Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21 WAF1/CIP1, independent of p53. J Biol Chem 2004; 279: 16000-16006.

Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with Dexamethasone Increases Anti-tumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts: In Vivo Activity, Pharmacokinetics and Clinical Implications for Cancer Chemotherapy. Clin Cancer Res. 2004; 10: 1633-1644.

Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner J, Agrawal S, Zhang R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res. 2004; 10: 1263-1273.

Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003;100:11636-41.

Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu F, Tang J, Wang H, Huang H, Zhang R, Agrawal S. Divergent Synthetic Nucleotide Motif Recognition Pattern: Design and Development of Potent Immunomodulatory Oligodeoxyribonucleotide Agents with Distinct Cytokine Induction Profiles. Nucleic Acid Res. 2003; 31: 2393-2400.

Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Anti-tumor Efficacy of A Novel Antisense Anti-mdm2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms. Mol Med 2002; 8: 185-199.

Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms. Clin Cancer Res 2001; 7: 3613-3624.

Zhang R, Wang H. MDM2 Oncogene as a Novel Target for Human Cancer Therapy. Current Pharmaceutical Design 2000; 6: 393-416.

Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RI subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999;96:13989-94.

Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998;95:195-200.

Lu Z, Zhang R, Carpenter JT, and Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1998; 4: 325-329.

Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998; 95: 195-200.

Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 1997;94:2620-5.

Cai Q, Rahn RO, Zhang R. Dietary flavonoids quercetin, luteolin, and genistein reduce oxidative DNA damage and lipid peroxidation and quench free radicals. Cancer Lett 1997; 119: 99-107.

Zhang X, Zhang R, Zhao H, Cai H, Gush KA, Kerr RG, Pettit GR, Kraft AS. Preclinical pharmacology of the natural product anticancer agent Bryostatin 1, an activator of protein kinase C. Cancer Res 1996; 56: 802-808.

Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu, T, Saag, MS, Jiang Z, Temsamani J, Martin RR, Schechter P, Agrawal S, Diasio RB. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 1995; 58: 44-53.

Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995; 58: 512-522.

Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-5438.

Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. J Clin Oncol 1993; 11: 1609-1617.

Zhang R, Lu Z, Diasio, CR, Liu T, Soong S-j. The time of administration of 3’-azido-3’-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy. Antimicrob Agents Chemother 1993; 37 (9): 1771-1776.

Zhang R, Lu Z, Liu T, Soong S-j, Diasio RB. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes. Possible relevance to fluoropyrimidine chemotherapy. Cancer Res 1993; 53: 2816-2822.

Lu Z, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992; 267 (24): 17102-17109.

Zhang R, Barnes S, Diasio RB. Differential intestinal deconjugation of taurine- and glycine-conjugated bile acid N-acyl amidates in rats. Am J Physiol 1992; 262: G351-G358.

Selected Book Chapter and Editorials

Zhang R. Special Issue, MDM2 in Cancer Prevention and Treatment. Cells, 2019-2020

Zhang R. Preface: Scientific Premise and Rigors in Scientific Research, Peer Review, Editing and Publishing. Curr Cancer Drug Targets 2017; 17(1): 2.

Qin JJ, Wang W, Zhang R. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Progress in Molecular Biology and Translational Science. 2017; 151: 195-216

Wang W, Nag S, Zhang R. Pharmacodynamics and Pharmacokinetics in Breast Cancer Animal Models. Methods Mol Biol 2016; 1406: 271-287.

Zhang R. Editorial: Artemisinin (Qing Hao Su), Nobel Prize, Anti-Malaria, and Beyond. Chin J Nat Med 2016; 14 (1):1-2.

Zhang R and Nag S: Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Sciences in Special volume in book series in Advances in Pharmaceutical Sciences, Pharma-Nutrition; eds. Johan Garssen & Gert Folkerts, Springer, 2014; pp 304-345.

Zi X and Zhang R (Guest Editors): Hot Topic Issues: Anticancer Molecular Targets of Natural Products. Curr Cancer Drug Targets 2013. Vol. 13; Issue 5.

Zhang R. Genistein. Encyclopedia of Cancer. Ed. M. Schwab. Springer Berlin Heidelberg. Pp1533-1534; 2012

Zhang R, Buckoreelall K, Rayburn ER. Target Protein Database-p53; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Venn AR, Zhang Z, Rayburn ER. Target Protein Database-PA28gamma (PSME3); Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Venn AR, Rayburn ER. Target Protein Database-PA28beta (PSME2)l; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Venn AR, Rayburn ER. Target Protein Database-PA28alpha (PSME1); Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Buckoreelall K. Target Protein Database-XIAP; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Ezell SJ. Target Protein Database-MDM4/MDMx; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R, Rayburn ER. Target Protein Database-MDM2; Current BioData Ltd, Middlesex House, London, UK; online 2008

Zhang R and Rayburn E. Linkage between Toxicology of Drugs and Metabolism. In: Preclinical Safety Handbook: ADME and Biopharmaceutical Properties. Ed. Shayne C. Gad, John Wiley and Sons, Hoboken, NJ, 2008; pp 975-1008.

Zhang R and Wang H. Antisense Strategies for the Development of Novel Cancer Therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. Novel Anticancer Agents Strategies for Discovery and Clinical Testing. Elsevier Science, New York, NY, ISBN: 0-12-088561- 1. 2006; pp 193-206.

Zhang R. Guest editor, MDM2 As A Novel Cancer Drug Target, Curr Cancer Drug Targets, Vol 5, Number 1, February 2005

Zhang R and Wang H. Antisense Technology. In: D. T. Curiel and J.T. Douglas: Contemporary Cancer Research: Cancer Gene Therapy. Humana Press, Totowa, NJ, 2004; pp 35-49.

Zhang R and Wang H. Modulation of Gene Expression by Antisense Oligonucleotides. In: S. W. Kim and R.I. Mahato eds: Pharmaceutical Perspectives of Nucleic acid-based Therapeutics. Taylor & Francis: London, UK, 2002; pp. 33-53.

Zhang R. Guest editor, Antisense Oligonucleotide Therapeutics, Curr Cancer Drug Targets, Vol 1, Number 3, November 2001.

Agrawal S and Zhang R, Pharmacokinetics and Bioavailability of Oligonucleotides following Oral and Colorectal Administrations in Experimental Animals. In: Antisense Research and Applications (Crooke S ed.), Springer-Verlag, Heidelberg, 1998; pp.525-543.

Zhou H and Zhang R. Guide to Research and Development of New Drugs. China Medical and Pharmaceutical Press, Beijing, 1997.

Agrawal S and Zhang R, Pharmacokinetics of Phosphorothioate Oligonucleotide and its Novel Analogs. In: Antisense Oligodeoxynucleotides and Antisense RNA as Novel Pharmacological and Therapeutic Agents (Weiss B. Ed.) CRC Press, 1997, pp. 58-78.

Agrawal S and Zhang R, Pharmacokinetics of Oligonucleotides. In: Oligonucleotides as Therapeutic agents (Chadwick DJ and Cardew G, Eds.) Ciba Foundation Symposium 209, Wiley, Chichester, 1997, pp. 60-78.

Diasio RB, Lu Z, Zhang R, Shihanian, H. Fluoropyrimidine Catabolism. In: Concepts, Mechanisms, and New Targets for Chemotherapy (Muggia F, ed.) Kluwer Academic Publishers, Boston, MA, 1995, pp.71-93.

Zhang R. Circadian based infusional chemotherapy. J Infusion Chemother, 4: 67-68, 1994.

Zhang R, Diasio RB. Pharmacologic Basis for Circadian Pharmacodynamics. In: Circadian Cancer Therapy (Hrushesky WJM, ed.), CRC Press, 1994, pp. 61-103.

Selected Patents

Cancer treatment utilizing SP-141 to bind with MDM2 and act as an inhibitor of MDM2 expression (US Patent 10,472,355, 2019)

1-Aryl-OR 1-heteroaryl-pyrido[b]indoles and uses thereof (U.S. patent application Serial No. 12/799,485; filed 4-26-2010; USPTO Publishing Date: 12-16-2010; #2010/0317667A1)

Marine alkaloid makaluvamines and derivatives thereof (U.S. patent application Serial No. #20100144779/514292; filed 2-23-2007; amended 2-23-2008; USPTO Publishing Date: 06/10/10; #US2010/0144779 A1)

Stabilization of p53 by Ribosomal Protein S7 (U.S. patent application Serial No. 60/889,110; filed 2-9-2007)

PA28y Regulation in Cells (U.S. patent application Serial No. 60/888,953; filed 2-9- 2007; WO 2008/121442 A2)

Novel Ginsenoside Compounds Compositions and Methods of Use (U.S. patent application Serial No. 60/870,250; filed 12-15-2006; WO 2008/076900 A1)

Methods and compositions related to increasing antitumor activity of chemotherapeutic agents. (U.S. patent application No. 60/567,766, filed on May 3, 2005).

Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides. (US patent filed, No. 08/846, 427, 04/30/97; Patent Number EP 1 007098 B1)

Methods of down-regulating gene expression. (US Patent No. 6,936,593, 8/30/2005)

MDM2-Specific Antisense Oligonucleotides (US Patent No. 6,946,447, 9/20/2005)

Methods of down-regulating gene expression. (US Patent No. 6,608,035, 8/19/2003)

MDM2-Specific Antisense Oligonucleotides (US Patent No. 6,013,786, 1/11/2000)

Use of 2’-substituted oligonucleotides to down-regulate gene expression. European Patent Application Serial No. 95938213.6, filed 10/17/95, Case No. 178.0, Issued 12/15/99; Patent Number EP 0 788 366 B1.

A method for down-regulating gene expression. (US Patent No 5, 591,721, 1/7/1997)

DIHYDROPYRIMIDINE DEHYDROGENASE COMPOSITIONS AND METHODS OF USE- WO Patent 1,995,028,489, 1995

Selected Invited Lectures (since 2015)

University of Texas Medical Branch: Targeting MDM2-p53 pathways for cancer therapy. Galveston, TX, Sept 27, 2019

American Chemical Society at University of Houston: Cancer Drug Discovery: A Case Study of Targeting P53-MDM2 Pathway. Houston, TX, Sept 24, 2019

Penn State University: Targeting MDM2-p53 pathway for cancer prevention and therapy. Philadelphia, PA, Sept 12, 2019

International Symposium on Cancer Metabolism & Precision Cancer Therapy: Distinguished Speaker: Targeting Oncogene, Metabolism, and Inflammation Pathways for Cancer Therapy, Chongqing, China, August 15-20, 2019

Baylor College of Medicine: Targeting MDM2-p53 pathway for cancer prevention and therapy. Houston, TX, August 6, 2019

SCBA International Symposium 2019: Co-Chair and Invited Speaker: Targeting Inflammation and Oncogene for Pancreatic Cancer Therapy. Kunming, China, July 24-28, 2019

JMCB International Symposium 2019: The Legend of p53 vs. Cancer: Session IV (p53 and Oncogenes in Translational Cancer Medicine) Chair and Invited Speaker: Targeting MDM2 oncogene for cancer therapy, Hangzhou, China, May 10-12, 2019

World DNA and Genome Day-2019: Moderator of Nobel Laureate Forum and Keynote Forum and Keynote Speaker: DNA-and RNA-Based Therapy: A 40-Year Learning Curve, Nanjing, China, April 25-27, 2019

Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center: Targeting Inflammation and Oncogene Pathways for Cancer Prevention and Therapy. New Orleans, LA, Jan 17, 2019

Rutgers Health Cancer Institute of New Jersey: Targeting MDM2 Oncogene for Cancer Therapy and Prevention. Newark, NJ, November 14, 2018

The 8th International MDM2 Symposium: Invited Speech: Targeting Inflammation and Oncogene for Cancer Therapy, Tampa, FL, November 3, 2018

SCBA International Conference 2018: Invited Keynote Speech: One Stone Two Birds: Targeting Inflammation and Oncogene Pathways for Cancer Therapy, Taiyuan, China, September 21, 2018

The Second International Summit on Medical Research and Publication: Invited Keynote Speech: Critical elements in biomedical writing, Wuhan, China, September 25, 2018

University of Pittsburg College of Pharmacy: Targeting MDM2 Oncogene for Cancer Therapy. Pittsburg, PA, May 22, 2018

SCBA-TX Annual Symposium: Targeting MDM2-p53 pathway for cancer therapy: A 20+-year learning curve. Houston, TX, May 12, 2018

University of Texas Health Science Center at Houston: Targeting MDM2 Oncogene for Cancer Prevention and Therapy. Houston, TX, Feb 5, 2018

Rosalind Franklin University of Medicine and Science, Haim G. and Jane Graumann Nagirner Weinstein Symposium Series: Targeting NFAT1-MDM2 Pathway for Cancer Prevention & Therapy. Chicago, IL, September 18, 2017

The Fourth Annual Conference of Chinese Society of Micro- & Nanoscience and Technology/ the 2016 International Conference of Nanobiology and Nanomedicine: Nano-delivery of Novel Anti-MDM2 Agents for Breast Cancer and Pancreatic Cancer Therapy. Fuzhou, China. December 7-10, 2016.

The 8th International MDM2 Workshop: Invited Speech: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-Year Learning Curve. New Orleans, LA. November 1-4, 2015.

The First International Summit on Medical Research and Publication (FISOMRAP): Keynote Speech: Making a Competitive Grant Application: Innovation and Study Design. Wuhan, China. October 17-18, 2015.

The 3rd International Conference on Biomedical Engineering and Pharmaceutical Science (ICBEPS2015): Keynote speech, "Discovery and Development of MDM2 Inhibitors for Cancer Prevention and Therapy." Nanjing, China. September 20-22, 2015.

University of Oklahoma Health Sciences Center: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: Oklahoma City, OH, August 21, 2015.

The 15th SCBA International Symposium: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year learning curve. Taipei, Taiwan, June 26-29, 2015.

International Conference on Bioinformatics and Biostatistics in Cancer Genomics Research (BBACGR2015): Keynote Speech: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year Learning Curve. Doha, Qatar, April 26-28, 2015.

University of Tennessee Health Sciences Center: Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-year Learning Curve. Memphis, TN, January 12, 2015.

Selected Published Abstracts (since 2015)

Wang W, Cheng JW, Qin JJ, Hu B, Nijampatnam B, Velu SE, Yang XR, Fan J, Zhang R. Inflammation and oncogene in hepatocellular carcinoma: Clinical relevance and experimental targeted therapy. AACR annual meeting, Atlanta, GA, March 29-April 3, 2019

Wang W, Hu B, Qin JJ, Cheng, J, Li X, Hu M, Fan J, Tang XR, Zhang R. Treating Hepatocellular Carcinoma Metastasis and Overcoming Chemoresistance through Inhibiting the MDM2 Oncogene. AACR annual meeting, Chicago, IL, April 14-17, 2018

Qin JJ, Li X, Wang W, Zhang R. Targeting the NFAT1-MDM2-MDMX Network for Prostate Cancer Therapy. AACR annual meeting, Chicago, IL, April 14-17, 2018

Wang W, Zhang R. Targeting NFAT1-MDM2-p53 pathway for cancer therapy. The 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Munich, Germany. November 29-December 2, 2016.

Wang MH, Feng L, Zhang R, Yao HP. Humanized anti-RON ADC for targeted cancer therapy: Commercial development toward investigational new drug clearance. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Qin JJ, Wang W, Sarkar S, Zhang R. Oral Delivery of Anti-MDM2 Inhibitor SP141 with FcRn-targeted Nanoparticles to Treat Breast Cancer and Metastasis. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Qin JJ, Sarkar S, Voruganti S, Wang W, Zhang R. Identification of Lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for cancer therapy. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Qin JJ, Wang W, Sarkar S, Voruganti S, Zhang R. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. TTUHSC SOP Research Days, Amarillo, TX, June 1-2, 2016.

Wang W, Voruganti S, Qin JJ, Qian B, and Zhang R. RYBP predicts survival of patients with non-small cell lung cancer and sensitizes chemotherapy. Submitted to AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5-9, 2015.

Wang W, Zhang R. Involvement of RYBP in Growth and Response to Chemotherapy in Non-Small Cell Lung Cancer (#PB50). 15th SCBA International Symposium, Taiwan, June 26-29, 2015.

Zhang R. Targeting MDM2 Oncogene for Cancer Prevention and Therapy: A 20-Year Learning Curve. 15th SCBA International Symposium, Taiwan, June 26-29, 2015.

Wang W, Qin JJ, Voruganti S, Zhang R. Novel MDM2 Inhibitor for Breast Cancer Therapy: Where We Are and Where To Go? TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015.

Qin JJ, Wang W, Cheng J, Voruganti S, Nag S, Fan J, Gao Q, Zhang R. RYBP as a novel target for cancer gene therapy and biomarker for prognosis. TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015 (Best Poster Presentation-Post-Doc Associates).

Qin JJ, Wang W, Voruganti S, Zhang R. Identifying a novel natural product MDM2 inhibitor for breast cancer therapy. TTUHSC SOP Research Days, Amarillo, TX, June 11- 12, 2015 (Best Poster Presentation-Post-Doc Associates).

Voruganti S, Qin JJ, Wang W, Zhang R. Combination therapy with Adv-RYBP and chemotherapy in lung cancer. TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015 (Best Poster Presentation-Sr. PhD Students).

Voruganti S, Qin JJ, Sarkar S, Nag S, Walbi IA, Wang S, Zhao Y, Wang W, Zhang R. Oral Nano-Delivery of Natural Anticancer Ginsenosides. TTUHSC SOP Research Days, Amarillo, TX, June 11-12, 2015 (Best Poster Presentation-Sr. PhD Students).

Ibrahim-Alobaide MA, Alobydi H, Abdelsalam AG, Zhang R, Sivenugopal KS. Characterization of a complex 5’-regulatory region of the cancer associated gene B4GALT1 and its comparison with the gene family. International Conference on Bioinformatics and Biostatistics, Applications in Genomics Research, Qatar, April 26-28, 2015.

Ibrahim-Alobaide MA, Abdelsalam AG, Alobydi H, Rasul KI, Zhang R, Sivenugopal KS. Structural features of alternative promoters of cisplatin resistance genes. International Conference on Bioinformatics and Biostatistics, Applications in Genomics Research, Qatar, April 26-28, 2015.

Zhang R. Targeting MDM2 oncogene for cancer therapy: A 20-year learning curve. International Conference on Bioinformatics and Biostatistics, Applications in Genomics Research, Qatar, April 26-28, 2015.

Alobaide MA, Alobydi H, Abdelsalam Abdelsalam A, Zhang R, Srivenugopal KS. Multiple alternative promoters and a long non-coding RNA constitute the complex regulatory region of the cancer and drug resistance associated gene B4GALT1. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Voruganti S, Qin JJ, Wang W, Zhang R. The anticancer activity of Japonicone A is mediated by inhibiting NFAT1-MDM2 pathway. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Qin JJ, Wang W, Voruganti S, Zhang R. A novel MDM2 inhibitor suppresses breast cancer growth and metastasis. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Wang W, Chen J, Qin JJ, Voruganti S, Nag S, Fan J, Gai Q, Zhang R. VRYBP Expression Predicts Survival of Patients with Hepatocellular Carcinoma, and Regulates Response to Chemotherapy. AACR annual meeting, Philadelphia, PA, April 18-22, 2015.

Memberships

  • Fellow, National Academy of Inventors
  • Fellow, American Association for the Advancement of Science (AAAS)
  • Fellow, Molecular Medicine Society
  • Diplomate and Board Director (2009-2013), American Board of Toxicology
  • Member, American Association for Cancer Research (AACR); American Society of Clinical Oncology (ASCO); American Society for Biochemistry and Molecular Biology (ASBMB); American Association of Pharmaceutical Scientists (AAPS)
  • Life Member, Cancer Division Officer, Society of Chinese Bioscientists in America (SCBA)
  • Former Member, American Society for Clinical Pharmacology and Therapeutics (ASCPT); American College of Toxicology (ACT); American Society for Microbiology (ASM); American Chemical Society (ACS); Drug Information Association (DIA); International Society for Nucleosides, Nucleotides, and Nucleic Acids (IS3NA)

Editorial Appointments

  • Editor-in-Chief: Current Cancer Drug Targets, 2013-present; Medjaden Bioscience, 2005-present
  • Associate Editor-in-Chief: Journal of Nutritional Oncology, 2016-2018; Chinese Journal of Natural Medicines, 2015-2017
  • Associate Editor: Frontiers in Pharmacology, 2010-present; Therapeutics and Clinical Risk Management, 2004-2018; Journal of Biomedical Research, 2015-2018
  • Senior Editorial Board Member: International Journal of Biochemistry and Molecular Biology, 2009-present
  • Senior Advisory Board, Environmental Health Perspectives, USA (Chinese Edition), 2010-present
  • Editorial Board Member: Pharmaceuticals & Drug Designing, 2014-present; Current Biotechnology, 2014-present; Genes and Diseases, 2014-present; Journal of Biomedical Research, 2013-present; Journal of Bioequivalence & Bioavailability, 2013-present; Drug Intoxication & Detoxification: Novel Approaches, 2012-present; Drug Discoveries and Therapeutics, 2011-present; The Open Biomarker, 2008-present; Advances in Pharmacological Sciences, 2008-present; The Open Cancer Journal, 2006-present; Scientific Journals International, 2005-present; Current Medicinal Chemistry-Anti-Cancer Agents, 2005-present; Recent Patent Reviews on Anti -Cancer Drug Discovery, 2005-present; Journal of Biological Sciences, 2004-present; Current Medicinal Chemistry, 2004-present; Medicinal Chemistry, 2004-present; Medicinal Chemistry Reviews -Online, 2003-present; Letters in Drug Design and Discovery, 2002-present
  • Reviewer: Acta Anaesthesiologica Scandinavica; Acta Pharmacologica Sinica; Acta Physiologiae Plantarum; Aging; Biochemical Pharmacology; Biochim Biophys Acta; Biological Procedure-online; Biomaterials; Bioorganic and Medicinal; Chemistry; Breast Cancer Research; Breast Cancer Research and Treatment; British Journal of Pharmacology; British Journal of Nutrition; Cancer; Cancer Biology & Therapy; Cancer Epidemiology, Biomarkers and Prevention; Cancer Letters; Cancer Research; Cancer Treatment Reviews; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Research; Clinical Cancer Research; Clinical Drug Investigation; Clinical Pharmacology and Therapeutics; Current Pharmaceutical Design; Current Pharmacogenomics; Cutaneous and Ocular Toxicology; Environmental Health Perspective; Environmental Pollution; Environmental Toxicology; European Journal of Medicinal Chemistry; Evidence-Based Complementary and Alternative Medicine; Expert Opinion on Drug Discovery; Expert Opinion on Therapeutic Patents; Expert Opinion on Therapeutics; Expert Reviews in Molecular Medicine; Food and Chemical Toxicology; Free Radical Biology and Medicine; Gynecological Oncology; Hepatology; Indian Journal of Medical Research; Investigational New Drugs; International Journal of Biological Sciences; International Journal of Biological Markers; International Journal of Cancer; International Journal of Medical Sciences; Journal of Biomedical Material Research (Part A); Journal of Biomolecular Screening; Journal of Biotechnology; Journal of Cellular Physiology; Journal of Cellular and Molecular Medicine; Journal of Chemical Information and Modeling; Journal of Clinical Oncology; Journal of Clinical Pharmacy and Therapeutics; Journal of Controlled Release; Journal of Ethnopharmacology; Journal of Gastroenterology and Hepatology; Journal of Medicinal Chemistry; Journal of Molecular Medicine; Journal of Nutritional Biochemistry; Journal of Liposome Research; Journal of Pharmaceutical Science; Journal of Pharmacology and Experimental Therapeutics; Liver International; Leukemia Research; Medicinal Chemistry Communications; Molecular Cancer; Molecular Cancer Research; Molecular Cancer Therapeutics; Molecular Carcinogenesis; Molecular and Cellular Biochemistry; Molecular Medicine; Molecular Nutrition and Food Research; Molecular Pharmacology; Neural Plasticity; Natural Product Research; Neoplasia; Neuroimmunomodulation; Nucleic Acids Research; Nutrition Journal; Oligonucleotides; Oncogene; Oncotarget; Pharmaceutical Development and Technology; Pharmaceutical Research; Pharmacologica Sinica; Phytotherapy Research; Planta Medica; PlosOne; Rapid Communications in Mass Spectrometry; Science Translational Medicine; Scientific Journals International; Southern Medical Journal; Therapeutic Delivery; Toxicological Sciences; Toxicology Letters; Toxicology Reports; Tumor Biology